A peptide HIV fusion inhibitor that blocks viral entry into cells. First approved drug in the fusion inhibitor class.

Is Enfuvirtide FDA approved?

Yes, Enfuvirtide is FDA approved. FDA Approved - HIV salvage therapy

What are the side effects of Enfuvirtide?

Reported side effects of Enfuvirtide include: Injection site reactions (98%), Diarrhea, Nausea, Fatigue, Pneumonia (higher incidence), Hypersensitivity reactions, FDA approved (Fuzeon).

What is the typical dosing for Enfuvirtide?

FDA-approved dosing. Common doses observed in research: 90 mg subcutaneous twice daily. Duration: Ongoing as part of HIV regimen. Administration: Subcutaneous injection twice daily.

Immune

Enfuvirtide

Also known as: Fuzeon, T-20

FDA Approved

Popular For

HIV treatment, viral infection management

Key Facts: Enfuvirtide

Category: Immune
FDA Status: FDA Approved
Clinical Status: FDA Approved - HIV salvage therapy
Administration: Subcutaneous injection twice daily
Typical Dose: Limited community data available
Frequency: See research protocols
Evidence Level: FDA Approved
Duration: Ongoing as part of HIV regimen

Also Known As

Fuzeon, T-20

Mechanism of Action

Enfuvirtide is a 36-amino acid peptide that binds to HIV gp41, preventing the conformational change needed for virus-cell membrane fusion. This blocks HIV entry before the virus can infect the cell.

Research Summary

TORO trials showed significant viral load reduction in treatment-experienced patients. Reserved for salvage therapy due to twice-daily injection requirement and injection site reactions.

Clinical Status:FDA Approved - HIV salvage therapy

Trial Progress:FDA Approved

Pre

III

FDA

Dosing Information

FDA Approved·Human clinical trials completed, FDA approved

Typical DosingⓘDoses commonly used by people in practice, based on community reports and anecdotal experience.

Community experience

Common Dose

Limited community data available

Range

See research dosing

Frequency

See research protocols

Research DosingⓘDoses from published scientific studies and clinical trials. May include human or animal research.

Scientific studies

FDA-approved dosing

Doses from Studies

90 mg subcutaneous twice daily

FDA Approved Labeling - Prescribed dose ↗

Duration

Ongoing as part of HIV regimen

Administration

Subcutaneous injection twice daily

Timing & Administration

Best Time to Take

Morning or as directed

Follow recommended protocol

Food Recommendation

With or without food

Why This Timing?

Timing may vary based on individual response and goals. Consistency is generally more important than specific timing.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

●Injection site reactions (98%)
●Diarrhea
●Nausea
●Fatigue
●Pneumonia (higher incidence)
●Hypersensitivity reactions
●FDA approved (Fuzeon)

References

Related Peptides

Peptides commonly compared with Enfuvirtide or used in similar applications.

LL-37

Clinical Trials

A naturally occurring antimicrobial peptide and the only human cathelicidin. Part of the innate immune system with broad-spectrum antimicrobial activity.

Immune

Thymosin Alpha-1

Clinical Trials

A naturally occurring thymic peptide that enhances immune function. Approved in over 35 countries for hepatitis B/C and as an immune adjuvant.

Immune

KPV

Preclinical

A tripeptide derived from alpha-melanocyte stimulating hormone (α-MSH). Known for potent anti-inflammatory effects, particularly in the gut.

Immune

VIP

Clinical Trials

A naturally occurring peptide with immunomodulatory and anti-inflammatory effects. Being studied for ARDS, pulmonary hypertension, and autoimmune conditions.

Immune

PNC27

Preclinical

A chimeric anti-cancer peptide containing p53 residues 12-26 linked to a membrane-penetrating sequence. Selectively kills cancer cells by binding to HDM-2 expressed on cancer cell membranes, inducing membrane pore formation and necrosis while leaving normal cells unaffected.

Immune

Thymogen

Clinical Trials

A synthetic dipeptide (Glu-Trp) bioregulator derived from Thymalin, a thymus extract. One of Professor Khavinson's key immunomodulatory peptides, shown to stimulate T-lymphocyte development and normalize immune function. Has been used clinically in Russia for immune support.

Immune

How to Use Enfuvirtide Enfuvirtide Alternatives Compare with Similar Browse All Peptides

Looking for a trusted vendor?

Pro members get access to verified vendors with quality standards & exclusive discount codes.

View Verified Vendors

PRO

Want updates on Enfuvirtide research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Back to all peptides